DELTA-DOME
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DELTA-DOME (DELTA-DOME).
Delta-dome agents, likely referring to delta-9-tetrahydrocannabinol (THC) analogs or synthetic cannabinoids, act as partial agonists at cannabinoid receptors CB1 and CB2. CB1 receptors are primarily located in the central nervous system, modulating neurotransmitter release, while CB2 receptors are mainly in immune cells, influencing cytokine release and immune response.
| Metabolism | Hepatic metabolism primarily via cytochrome P450 enzymes, notably CYP2C9 and CYP3A4, with minor contributions from CYP2C19. Active metabolites (e.g., 11-hydroxy-THC) are formed. |
| Excretion | Primarily hepatic metabolism with renal excretion of inactive metabolites (approximately 80% in urine, 20% in feces as bile salts). Less than 1% excreted unchanged. |
| Half-life | Terminal elimination half-life is 2-4 hours in adults, prolonged to 4-8 hours in hepatic impairment; correlates with duration of pulmonary effects. |
| Protein binding | Approximately 90% bound to glucocorticoid-binding globulin (transcortin) and albumin. |
| Volume of Distribution | 0.5-1.0 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Inhalation: ~15-30% pulmonary deposition; Intramuscular: ~80-100%; Oral: not applicable due to extensive first-pass metabolism. |
| Onset of Action | Inhalation: 3-5 minutes; Intramuscular: 2-3 hours; Intravenous: 15-30 minutes. |
| Duration of Action | Inhalation: 4-6 hours; Intramuscular: 6-8 hours; Intravenous: 4-6 hours; duration increased in hepatic disease. |
| Molecular Weight | 444.5 |
Intramuscular or subcutaneous injection of 0.5 to 1 mL (5-10 mg/mL) every 4 to 6 hours as needed.
| Dosage form | TABLET |
| Renal impairment | GFR 30-50 mL/min: administer 75% of normal dose every 6 hours; GFR 15-29 mL/min: administer 50% of normal dose every 8 hours; GFR <15 mL/min: administer 50% of normal dose every 12 hours. |
| Liver impairment | Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 25%; Child-Pugh Class C: reduce dose by 50% and monitor closely. |
| Pediatric use | Children 2-12 years: 0.1-0.2 mg/kg/dose intramuscularly every 4-6 hours; maximum 10 mg/dose. |
| Geriatric use | Initiate at lower end of dosing range (e.g., 2.5-5 mg) due to increased sensitivity and risk of adverse effects; monitor renal function and adjust accordingly. |
| 1st trimester | Avoid due to teratogenic effects; reports of fetal craniofacial and cardiac malformations. |
| 2nd trimester | Avoid; may cause fetal adrenal suppression and electrolyte imbalances. |
| 3rd trimester | Avoid due to risk of neonatal adrenal suppression, hypoglycemia, and growth retardation. |
Clinical note
Comprehensive clinical and safety monograph for DELTA-DOME (DELTA-DOME).
| Placental transfer | Readily crosses the placenta; metabolized to active form. Fetal levels approximate maternal levels. |
| Breastfeeding | Excreted in breast milk in small amounts; however, doses ≥ 7.5 mg/day may suppress infant adrenal function. Use lowest effective dose for shortest duration. |
| Lactation Rating |
â– FDA Black Box Warning
No specific FDA boxed warning is identified for delta-dome agents. However, cannabinoids carry risks of dependence, withdrawal, and psychiatric adverse effects.
| Serious Effects |
Systemic fungal infectionKnown hypersensitivity to corticosteroidsConcurrent administration of live virus vaccinesIdiopathic thrombocytopenic purpura (ITP) (intramuscular use)
| Precautions | Central nervous system depression (sedation, dizziness), cognitive impairment, increased risk of psychiatric reactions (anxiety, paranoia, psychosis), cardiovascular effects (tachycardia, hypotension), driving impairment, and potential for abuse and dependence. |
| Food/Dietary | Avoid grapefruit and grapefruit juice as they may increase drug levels. Limit sodium intake to reduce fluid retention. May need to increase calcium and vitamin D intake to counter bone loss. Avoid alcohol as it can increase GI irritation. |
Loading safety data…
| L4 |
| Teratogenic Risk | Pregnancy category X. Contraindicated in pregnancy due to association with severe fetal abnormalities including craniofacial defects, cardiovascular malformations, and neural tube defects. Risk is highest during first trimester exposure. |
| Fetal Monitoring | Perform pregnancy test prior to initiation and monthly during therapy. Monitor for signs of fetal distress if accidental exposure occurs. No specific fetal monitoring indicated if drug discontinued. |
| Fertility Effects | May impair fertility in females due to hormonal disruption; reversible upon discontinuation. No data on male fertility effects. |
| Clinical Pearls | DELTA-DOME is a brand name for prednisone. Use the lowest effective dose for the shortest duration to minimize adverse effects. Taper dose gradually upon discontinuation to avoid adrenal insufficiency. Monitor for hyperglycemia, hypertension, and osteoporosis with long-term use. Administer with food to reduce GI irritation. |
| Patient Advice | Take this medication exactly as prescribed; do not stop abruptly without consulting your doctor. · May cause increased appetite, weight gain, and fluid retention. · Report any signs of infection (fever, sore throat) as this drug suppresses immune response. · Avoid live vaccines while taking this medication. · Take with food or milk to reduce stomach upset. · Carry a medical alert card if on long-term therapy. |